By using our website you accept our cookies policy.Find out more

Innovate UK is to invest up to £16 million to grow the UK commercial capacity to manufacture viral vectors

Registration is closed
Funding details
Registration opens
23 Oct 2017, 00:00
Registration closes
08 Nov 2017, 00:00
15 Nov 2017, 00:00
Projects should range in size from total costs of £2 million to £6 million. Up to 100% funding available.
ISCF via Innovate UK

NEW: Innovate UK is to invest up to £16 million to grow the UK commercial capacity to manufacture viral vectors. This is to address the current and predicted shortfall in viral vector production, to increase UK competitiveness and productivity, and better position the UK to manufacture viral vectors. These should be used in the development of clinical cell and gene therapies for the treatment of human disease and disorders.

This competition is not a collaborative R&D funded competition; it is for capital investment. The business must lead and can carry out the project on their own or in collaboration with others (businesses, RTOs, Catapults, charities or academia). To lead an application you must be a UK based business of any size, carry out your project in the UK and have a GMP manufacturing facility for viral vectors for advanced therapy medicinal products.

The grant must be claimed before April 2018 and projects should range in size from total costs of £2 million to £6 million. The maximum funding for eligible project costs is up to 50% if you are a business (of any size), or up to 100% if you are a non-profit distributing research organisation.

Innovate UK will support organisations that can set out a clear vision of how they will encourage partnerships with companies, universities and other research establishments. Projects also need to demonstrate that the capital investment grant they’re requesting will advance the UK’s ability to produce viral vectors for use as an ATMP or in the development of cell-based ATMPs and encourage partnerships between public and private organisations, and maximise further investment.

The investment will be funded under the government’s Industrial Strategy Challenge Fund (ISCF), in particular the Medicines Manufacturing Challenge. This challenge is seeking to develop technologies for the manufacture of medicines that will speed up patient access to new drugs and treatments, building on the exporting strengths of the UIK biopharmaceutical sector.

Interim Challenge Director Medicines Manufacturing Dr Mike Sullivan and Alice Jackson carefully explains the competition scope and takes you through the application process in a very useful short webinar. We strongly recommend you watch this.


Key dates:

Final date for registration                                       08 November 2017 at Noon

Submission of the full application                          15 November 2017 at Noon

Decision to applicants                                            by end of 15 December 2017

To find out more please visit the competition page.


Still available are two other ISCF funding competitions including…

1. £30m competition for Advanced Therapies Treatment Centres to establish a network of 3 advanced therapies treatment centres in the UK. Deadline is November 1st 2017 at noon

2. £15m competition for Medicines Manufacturing (round 1) for innovative projects in medicines manufacturing solutions